Charles River Laboratories International. has filed a patent for hybrid amebocyte lysate compositions, both native and recombinant, for detecting and quantifying endotoxin in a sample. The patent claims have been canceled. GlobalData’s report on Charles River Laboratories International gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Charles River Laboratories International, In-silico drug discovery was a key innovation area identified from patents. Charles River Laboratories International's grant share as of September 2023 was 57%. Grant share is based on the ratio of number of grants to total number of patents.
Hybrid amebocyte lysate compositions for endotoxin detection
A recently filed patent (Publication Number: US20230258647A1) describes a method for preparing an amebocyte lysate composition. The method involves combining recombinant factor C, recombinant factor B, and recombinant pro-clotting enzyme to formulate the composition. At least one of these components is made by expression in a genetically modified host cell that prevents the addition of sialic acid. The patent claims that the amebocyte lysate composition remains stable in a salt solution.
The patent also describes a composition comprising the recombinant factor C, recombinant factor B, and recombinant pro-clotting enzyme, where at least one of these components lacks sialic acid. This composition is said to remain stable in a salt solution. The amino acid sequences of the recombinant factor C, recombinant factor B, and recombinant pro-clotting enzyme are derived from various species including Limulus polyphemus, Tachypleus gigas, Tachypleus tridentatus, or Carcinoscorpius rotundicauda. The patent provides specific amino acid sequences for each component.
The patent further discloses a method of producing the recombinant factor C protein. This method involves culturing a genetically modified host cell transfected with a vector containing a nucleic acid sequence encoding the factor C protein. The factor C protein is then purified from the cell culture. The recombinant factor C protein produced by this method is claimed to remain stable in a salt solution.
The patent also includes a host cell comprising a nucleic acid encoding the factor C protein. This host cell has been genetically modified to prevent the addition of sialic acid to the factor C protein. The host cell can be a mammalian host cell, such as a HEK293 cell, and may lack N-acetylglucosaminyltransferase I.
Additionally, the patent describes a kit for bacterial endotoxin testing. The kit includes the recombinant factor C protein, recombinant factor B, and a recombinant pro-clotting enzyme.
Overall, this patent presents methods and compositions for preparing an amebocyte lysate composition, producing recombinant factor C protein, and a kit for bacterial endotoxin testing. The use of genetically modified host cells and the absence of sialic acid in the components are highlighted as important features of these inventions.
To know more about GlobalData’s detailed insights on Charles River Laboratories International, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
